To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor Clinical Trial

Official title:
A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Status Completed

Clinical Trial Summary

The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-IPN01070 is a radiolabelled imaging agent to be used in association with Positron-Emission-Tomography (PET). 68Ga-IPN01070 is made of two main components: 1) IPN01070, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium-68, a radioisotope that combined with IPN01070 can be seen in the PET scanner.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gastro-Enteropancreatic Neuroendocrine Tumor
Neuroendocrine Tumors

Clinical Trial Details

NCT number	NCT03220217
Study type	Interventional
Source	Ipsen
Contact
Status	Completed
Phase	Phase 2
Start date	September 26, 2017
Completion date	August 5, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04614766` - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT05050942` - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET	Phase 3
Recruiting	`NCT03475953` - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06253897` - A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
Recruiting	`NCT03863106` - The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Active, not recruiting	`NCT03972488` - Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET	Phase 3
Terminated	`NCT03042780` - FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas	Phase 2
Active, not recruiting	`NCT03600233` - Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors	Phase 2
Completed	`NCT01423734` - The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Withdrawn	`NCT02779257` - Pasireotide Treatment for Neuroendocrine Tumor	Phase 4